Truffle Capital Reports Outstanding 2020 Stock Market Performance for Its Listed BioMedTech Portfolio Companies
1.2.2021 14:29:00 CET | Business Wire | Press Release
Truffle Capital:
1. Three leading BioMedTech companies, Founded or Co-Founded and Supported by Truffle Capital since Their Inception, Generate Outstanding Performance in 2020
As of today, Abivax (EPA: ABVX), Carbios (EPA: ALCRB) and Carmat (EPA: ALCAR), are collectively capitalizing €1.3 billion (497, 443 and 379 M€ respectively) and ranking among the best 2020 stock performers listed on Euronext Paris (including Carbios at the 1st position; among the companies capitalizing between €200 million and 2 billion; see table below). These three companies are all developing radical innovations aiming at revolutionizing the medical sector or the protection of the environment.
Here are the latest companies’ breaking news for these three companies:
-
November 19, 2020: Carbios, founded by Truffle Capital in 2011 develops industrial bioprocesses for the circular economy of plastics, Carbios made its first 100% recycled plastic bottle from textiles. Based in French region of Auvergne, Carbios published a major scientific article in Nature, was able to attract renowned corporate partners (L’Oréal, Michelin, Nestlé Waters, Novozymes, PepsiCo, Suntory Beverage & Food Europe), and is now at the industrial pilot stage.
Link: News/Carbios/First Plastic Bottle from Recycled Textile
Link: News/Carbios/Nature Cover Page
-
December 22, 2020: Abivax, founded by Truffle Capital in 2013, is developing innovative drugs to treat patients with inflammatory diseases, viral diseases and cancers. Abivax ABX464 drug candidate was declared a National Covid-19 Research Priority by the French government for its large international clinical trial, miR-AGE, launched last May with ABX464. This BioTech company already secured €84 million in funding over the year.
Link: News/Abivax/National Covid-19 Research Priority
-
December 23, 2020: Carmat, co-founded by Truffle Capital, Airbus and Pr Carpentier in 2008, designer and developer of the world's most advanced total artificial heart conceived to provide a therapeutic alternative for patients suffering from end-stage biventricular heart failure, obtained market approval in Europe (CE marking).
Link: News/Carmat/CE Marking
For detailed information regarding these companies, including risk factors, please refer to their respective websites (Carbios: www.carbios.fr; Abivax: www.abivax.com and Carmat: www.carmatsa.com).
These companies and their achievements are Truffle Capital's signature as an entrepreneur-investor company: sourcing radical innovations in biotechnology and medical devices from around the world to build leading companies in France and support them towards advanced development stages.
Philippe Pouletty, M.D. co-founder and CEO of Truffle Capital, mentions: “We are proud of these three French companies that would not have existed without Truffle. Contributing to saving lives or protecting our planet, thanks to exceptional scientific research and technologies and to international management teams, fosters the emergence of future World leaders in France, while generating a very good return on investment for Truffle Capital’s funds. We intend to amplify our efforts with our new BioMedTech and Medeor funds, to benefit patients around the world and our investors.”
2020 Stock Performance Ranking of Euronext Paris listed BioMedTech Companies, with a Market Capitalization between 200 million and 2 billion euros on 01/01/2020 |
Ranking | Company | 2020 Stock Performance (%) | Market Capitalization
|
1 | Carbios | 318% | 443 |
2 | AB Sciences | 276% | 752 |
3 | Inventiva | 219% | 572 |
4 | Valneva | 202% | 826 |
5 | Gensight Biologics | 187% | 304 |
6 | Cellectis | 56% | 1098 |
7 | Abivax | 53% | 497 |
8 | Carmat | 47% | 379 |
9 | Innate Pharma | -42% | 291 |
10 | DBV Technologies | -78% | 545 |
Index | 2020 Performance |
CAC 40 | -7% |
Next Biotech | -6% |
Sources: Price per share variation (%) from 12/31/2019 to 12/31/2020; market capitalization on 01/22/2021. Companies in the diagnostics sector or with market capitalizations less than 200 million euros or over 2 billion euros as of January 1, 2020 were excluded. This ranking was established based on Euronext data.
2. New BioMedTech Companies created by Truffle Capital in Major Healthcare Sectors
Truffle continues to create and support future BioMedTech leaders aiming to treat life threatening diseases. Truffle Early-Stage BioMedTech Funds, which closed at the end of 2019, have already enabled the financing of 8 BioMedTech companies built on promising radical innovations.
- Affluent Medical (Aix en Provence) is developing four minimally invasive medical devices to treat cardiac, vascular and urologic diseases, which are already at an advanced clinical development stage;
- Artedrone (Paris) is aiming to design revolutionary autonomous microrobots allowing interventional radiologists to treat or prevent cerebrovascular accidents without using catheters;
- Bariatek (Paris) is developing a minimally invasive medical device to treat obesity;
- Caranx Medical (Nice) is developing autonomous surgical robots, for vascular and abdominal surgery;
- Diaccurate (Paris) is developing novel anti-cancer and anti-viral drugs based on breakthrough immuno-oncology mechanisms;
- HoliStick Medical (Paris) is developing a medical device to close pathological holes between the right and left heart (PFO) in order to prevent strokes;
- PKMed (Lyon), is developing biocompatible 3D implants to enable local drug delivery or to promote the genesis of functional tissues and organs following cell therapy;
- Skinosive (Marseille) is developing bioadhesive technologies to increase the effectiveness and safety of UV filters and other dermato-cosmetic compounds.
3. MEDEOR, Truffle New Late-Stage BioMedTech Fund, expects a first closing before summer
Truffle new MEDEOR Fund aims to complement Truffle's BioMedTech financing tools for BioMedTech companies, from inception to commercial stages. It has a clear industrial objective: invest at least €600 million in future BioMedTech world leaders developing advanced-stage medical devices (pre-commercial or commercial stage, for 70%) or innovative drugs (phase II & III clinical studies, for 30%). MEDEOR will always be lead investor and major proactive shareholder and board member, to build in France technological leaders that will revolutionize surgery and medicine. French institutional investors and French government granted MEDEOR the “Tibi” label, a French government initiative to encourage LP’s to invest in the best funds.
Thanks to MEDEOR, Truffle Capital intends to continue to lead French BioTech and MedTech companies towards commercial and international medical success.
4. Truffle : a High Performance business model launched twenty years ago
Founded in 2001, Truffle Capital is an independent European Venture Capital firm focused on radical innovations in Life Sciences (MedTech and BioTech) and breakthrough technologies in the IT sector (FinTech and InsurTech). Truffle Capital's mission is to support the founding and development of young innovative companies capable of becoming tomorrow’s leaders. Chaired by Patrick Kron and managed by Dr. Philippe Pouletty and Bernard-Louis Roques, Co-Founders and Chief Executive Officers, Truffle Capital has raised more than €1.1 billion since its creation and has supported several dozens of companies in the life sciences and digital technology sectors. In 2019, Truffle Capital announced the raising of nearly €400 million for its early-stage institutional funds, including €250 million dedicated to BioMedTech.
2020 was marked by the launch of new innovative projects in its two areas of expertise (BioMedTech and FinTech/InsurTech) and by very significant advances in the field of Biotechnology and Medical Devices.
******
For more information: www.truffle.com — Twitter: @trufflecapital
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005496/en/
Contact information
Truffle Capital Investor Relations: Maud Lazare – maud@truffle.com
Media Relations Agency – DGM Conseil
Quentin Hua – quentin.hua@dgm-conseil.fr (+ 33 6 28 63 27 29)
Thomas de Climens – thomasdeclimens@dgm-conseil.fr (+33 6 14 50 15 84)
Hugues Schmitt – h.schmitt@dgm-conseil.fr
Olivier Labesse – labesse@dgm-conseil.fr
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Announces Results of the Annual General Meeting2.4.2026 16:49:00 CEST | Press Release
SES (the “Company”) held the Annual General Meeting (“AGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions, including the Company’s 2025 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total dividend amount comprises the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share), which has already been paid to shareholders on October 16, 2025. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on April 16, 2026. “I would like to sincerely thank our shareholders for their active engagement, visionary support and continued confidence in SES’ strategy,” said Adel Al-Saleh, CEO of SES. “The outcomes of today’s AGM underscore our shared commitment to a bold multi-orbit approach, with Medium Earth Orbit as the strategic backbone of a dynamically evolving global interco
Forrester: Three Years Into GenAI, Enterprises Are Still Chasing Its True Transformative Value2.4.2026 16:00:00 CEST | Press Release
According to Forrester’s (Nasdaq: FORR) latest report, Accelerate Your AI Voyage, most enterprises are struggling to turn growing AI adoption and investment into measurable business impact. One of the key factors holding businesses back is low artificial intelligence quotient (AIQ) — Forrester’s measure of AI aptitude — with many employees lacking a clear understanding of how to use AI. Other barriers include an overemphasis on productivity-focused use cases, difficulty measuring impact, and siloed adoption within individual functions. While these challenges can leave firms frozen in doubt or indecision, the wait-and-see approach to AI adoption is no longer viable. To unlock AI’s full potential, organizations need to focus on four key areas: Define the business outcomes and success metrics for what they want AI to achieve; identify specific use cases for AI deployment aligned to those business outcomes; establish a structured runway to plan, test, and strategically time the deployment
Andersen Consulting Adds Multiplica2.4.2026 15:30:00 CEST | Press Release
Andersen Consulting enters into a Collaboration Agreement with Multiplica, a digital consulting firm that helps organizations design, build, and scale impactful digital experiences. Founded in Spain with a presence in Latin America and the U.S., Multiplica focuses on user research and discovery, customer experience research, digital strategy, data modeling and analysis, report automation and data visualization, conversion rate optimization, product design, and user experience design. The firm helps organizations accelerate digital transformation by building digital capabilities, teams, and assets that advance expertise across digital products, consulting, and talent development. Multiplica enables clients to forecast emerging trends in digital experience and transform their businesses through enhanced digital channels and customer engagement. “Collaborating with Andersen Consulting represents an exciting opportunity to extend our reach and impact,” said David Boronat, CEO of Multiplica
The LYCRA Company Announces Strategic Partnership on Renewable LYCRA ® Fiber2.4.2026 15:00:00 CEST | Press Release
The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the apparel and personal care industries, today announced the signing of a strategic partnership agreement with Texhong International Group Limited (“Texhong”), one of the world’s largest suppliers of core-spun cotton textiles. Under the agreement, Texhong will exclusively partner with The LYCRA Company to bring Renewable LYCRA® fiber made with 30 percent plant-based content* to China’s core-spun yarn sector. This collaboration aims to accelerate the adoption of bio-derived spandex across the global apparel and textile industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402505834/en/ The LYCRA Company announced a strategic partnership with Texhong International Group for renewable LYCRA® fiber. Pictured at the signing ceremony held in Shanghai (left to right): Jason Wang, Vice President, Asia, The LYCRA Company, and Zhou Xia, Chief O
Brightfin Unifies Brand Following Proven Optics Merger, Delivering a New Standard for Technology Cost Optimization2.4.2026 15:00:00 CEST | Press Release
Brightfin today announced that, following its merger with Proven Optics, the combined company will operate under a single brand: Brightfin. The unified company brings together deep expertise in Technology Expense Management (TEM) and IT Financial Management (ITFM) to help organizations better understand, manage, and reduce total technology spend. Technology spending will exceed $6 Trillion this year, and for most organizations, it remains one of the least understood. CIOs can tell you what they’re spending. Far fewer can tell you whether it’s working. “Over the past several months, we’ve brought these two businesses together around a shared purpose: help enterprise businesses better understand and optimize their technology spend,” said Joel Martins, CEO of Brightfin. “What we are seeing now is a shift. Visibility alone isn’t enough. Teams need to be able to act, tied to real financial outcomes. See Clearly. Spend Better. That is our north star, and that is what our platform is built to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom